CryoPort (NASDAQ:CYRX) Shares Gap Down – Time to Sell?

26 Jan 2026, 21:18 by Kim Johansen · The Markets Daily

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $10.93, but opened at $10.37. CryoPort shares last traded at $10.4450, with a volume of 17,612 shares traded.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CYRX. UBS Group boosted their price target on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Needham & Company LLC lifted their price objective on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CryoPort currently has a consensus rating of “Moderate Buy” and an average target price of $12.83.

Check Out Our Latest Stock Analysis on CryoPort

CryoPort Price Performance

The firm has a market capitalization of $508.71 million, a P/E ratio of 8.68 and a beta of 1.54. The stock’s 50 day simple moving average is $9.80 and its 200 day simple moving average is $9.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The company had revenue of $44.23 million for the quarter, compared to the consensus estimate of $41.22 million. As a group, analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 11,570 shares of the business’s stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. The trade was a 12.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.10% of the stock is owned by company insiders.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of CryoPort by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after buying an additional 69,550 shares during the period. Millennium Management LLC raised its position in shares of CryoPort by 18.5% during the 3rd quarter. Millennium Management LLC now owns 2,620,906 shares of the company’s stock worth $24,846,000 after purchasing an additional 408,335 shares during the last quarter. Thematics Asset Management boosted its holdings in CryoPort by 12.8% in the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock worth $14,285,000 after buying an additional 216,937 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in CryoPort by 37.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after buying an additional 408,263 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after acquiring an additional 705,649 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.